Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Phathom Pharmaceuticals' Change in Accured Expenses fell 9015.73% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 480.21%. This contributed to the annual value of $34.9 million for FY2024, which is 44502.34% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $1.1 million for Q3 2025, which was down 9015.73% from $12.4 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $19.9 million during Q4 2024, with a 5-year trough of -$11.3 million in Q1 2023.
  • For the 4-year period, Phathom Pharmaceuticals' Change in Accured Expenses averaged around $3.8 million, with its median value being $3.9 million (2022).
  • In the last 5 years, Phathom Pharmaceuticals' Change in Accured Expenses soared by 20427.17% in 2024 and then plummeted by 9015.73% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Change in Accured Expenses stood at $3.9 million in 2022, then soared by 162.11% to $10.3 million in 2023, then skyrocketed by 94.24% to $19.9 million in 2024, then tumbled by 94.41% to $1.1 million in 2025.
  • Its Change in Accured Expenses stands at $1.1 million for Q3 2025, versus $12.4 million for Q2 2025 and -$7.0 million for Q1 2025.